Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Deciphera Pharmaceuticals, Inc is a biotechnology business based in the US. Deciphera Pharmaceuticals shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals employs 255 staff and has a trailing 12-month revenue of around USD$7.2 million.
|Latest market close||USD$66.18|
|52-week range||USD$33.1 - USD$71.11|
|50-day moving average||USD$51.3969|
|200-day moving average||USD$51.8512|
|Wall St. target price||USD$73|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.312|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||7.31%|
|1 month (2020-10-30)||13.97%|
|3 months (2020-08-28)||47.92%|
|6 months (2020-05-29)||12.99%|
|1 year (2019-11-29)||39.95%|
|2 years (2018-11-30)||153.86%|
|3 years (2017-11-30)||233.23%|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$7.2 million|
|Gross profit TTM||USD$25 million|
|Return on assets TTM||-36.05%|
|Return on equity TTM||-62.54%|
|Market capitalisation||USD$3.3 billion|
TTM: trailing 12 months
There are currently 4.2 million Deciphera Pharmaceuticals shares held short by investors – that's known as Deciphera Pharmaceuticals's "short interest". This figure is 10.6% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting Deciphera Pharmaceuticals shares can be evaluated.
Deciphera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Deciphera Pharmaceuticals shares currently shorted divided by the average quantity of Deciphera Pharmaceuticals shares traded daily (recently around 411862.20472441). Deciphera Pharmaceuticals's SIR currently stands at 10.16. In other words for every 100,000 Deciphera Pharmaceuticals shares traded daily on the market, roughly 10160 shares are currently held short.
However Deciphera Pharmaceuticals's short interest can also be evaluated against the total number of Deciphera Pharmaceuticals shares, or, against the total number of tradable Deciphera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Deciphera Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Deciphera Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1055% of the tradable shares (for every 100,000 tradable Deciphera Pharmaceuticals shares, roughly 106 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Deciphera Pharmaceuticals.
Find out more about how you can short Deciphera Pharmaceuticals stock.
We're not expecting Deciphera Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Deciphera Pharmaceuticals's shares have ranged in value from as little as $33.1 up to $71.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals's is 1.7314. This would suggest that Deciphera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.